NCT06713057View on ClinicalTrials.gov

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

July 1, 2026

Conditions

Locally Advanced Thyroid Gland CarcinomaThyroid Cancer

Interventions

DRUG

Cyclophosphamide+Pemetrexed+5-Fluorouracil

IV or PO

DRUG

Cyclophosphamide+Doxorubicin+5-Fluorouracil

IV or PO

DRUG

Vindesine + Cisplatin

IV or PO

DRUG

Doxorubicin + Cisplatin

IV or PO

DRUG

Doxorubicin + Cyclophosphamide + Cisplatin

IV or PO

DRUG

Docetaxel + Doxorubicin

IV or PO

DRUG

Paclitaxel + Carboplatin

IV or PO

DRUG

Paclitaxel + Doxorubicin

IV or PO

DRUG

Paclitaxel + Cisplatin

IV or PO

DRUG

Gemcitabine alone

IV or PO

Trial Locations (1)

610041

West China hospital, Chengdu

All Listed Sponsors

lead

West China Hospital

OTHER

NCT06713057 - Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer | Biotech Hunter | Biotech Hunter